SkinBioTherapeutics plc platform passes additional external toxicity tests

SkinBioTherapeutics plc LON:SBTX a life science company focused on skin health, has passed two additional and final third party cellular toxicity tests for its SkinBiotix(R) technology.

The in vitro tests, for photo-toxicity (sensitivity to sunlight) and ocular toxicity (effect on eye cells), follow on from the recent first stage cytotoxicity tests, as announced on 3 October 2017

The studies were again conducted by Charles River Laboratories, a Contract Research Organisation (CRO), in accordance with the OECD Principles of Good Laboratory Practice.

In the photo-toxicity test, the testers were looking to determine whether the SkinBiotix(R) technology would become toxic to cells when exposed to UV and visible light. The results showed that SkinBiotix(R) is non-phototoxic.

The second test, for ocular toxicity, was carried out to determine whether SkinBiotix(R) is toxic to eye cells. This involved measuring for two important components which are predictive of irritation, corneal opacity (cloudiness) and permeability (ability to let fluids pass through the eye). The SkinBiotix(R) technology also passed this test.

SkinBioTherapeutics will continue developing the technology towards the three applications in skin care, anti-infection and skin repair.

Dr Catherine O’Neill, CEO of SkinBioTherapeutics, commented: “Since announcing that the SkinBiotix platform passed the key cytotoxicity test in October, we have been focussing on further proving its efficacy. With this news today, the technology has passed the three necessary toxicity tests showing that it can be safely applicable across our three target markets. We are continuing formulation development and are confident about starting our human studies in 2018.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    SkinBiotherapeutics Plc

    More articles like this

    SkinBiotherapeutics Plc

    Why we should all be eating a microbiome diet

    First, let’s briefly talk about the microbiome. The gut microbiome refers to the trillions of bacteria that live within our gastrointestinal tracts. If you were to collectively bunch them all up into a ball, it would

    SkinBiotherapeutics Plc

    Microbiome-based therapy for eczema: On the horizon?

    Results of pre-clinical and early clinical trials conducted by investigators at the National Institutes of Health showing the effectiveness of using bacteria to treat eczema are paving the way for further study into the potential for

    SkinBiotherapeutics Plc

    SkinBioTherapeutics plc achieved significant manufacturing scale up

    Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented: “The progress we’ve made so far in manufacturing and freeze-drying the lysate is very encouraging. The current formulation is undergoing extended stability studies in preparation for the human study.”

    SkinBiotherapeutics Plc

    Protect your skin microbiome

    Like your gut, your skin also has a complex system of bacteria and fungi living on its surface. “It sounds weird and scary, but it’s actually good for you,” says Sarvenaz Zand, M.D., a dermatologist based

    SkinBiotherapeutics Plc

    What Is Dyshidrotic Eczema, Exactly?

    If you have found your way to this story, then there is a good chance you’re feeling the itch. Dyshidrotic Eczema is a common form of eczema that can crop up as crazy itchy blisters on

    SkinBiotherapeutics Plc

    Bacteria on your skin could speed healing

    Microbes on the surface of the skin help the immune system to respond to injury and heal wounds. Immunity research have historically focused on the response to pathogens and inflammation, and so relatively little is known

    SkinBiotherapeutics Plc

    Can you really use probiotics to fight acne?

    If you’ve ever had a breakout, you’ve likely tried to dry those suckers up with bacteria-killing washes and spot treatments. You know, because conventional wisdom (and lots of research) has shown that zits, particularly the big painful

    SkinBiotherapeutics Plc

    SkinBiotherapeutics is harnessing the power of Microbiome

    SkinBioTherapeutics (LON:SBTX) CEO Dr Cath O’Neill worked in the field of gastroenterology, investigating the effect of probiotics on the intestinal barrier function, an area which had already seen significant commercial success through health foods and yoghurt

    SkinBiotherapeutics Plc

    Skin Microbiome: Why You want Bacteria On Your Skin

    The gut gets the majority of the attention when we talk about the microbiome (even though your mouth has a vast microbiome as well!). The digestive system is home to trillions of organisms that can affect the body,